Friday, 16 October 2026European Markets

ADC SIIC Stock Went Up By Over 26% In The Last 10 Sessions

Loading stream...

shares of adc siic, a publicly owned real estate investment firm, have experienced an extraordinary 26.13% surge in just 10 sessions despite experiencing five straight days of losses. meanwhile, its cac 40 index which includes it saw its share prices slip 1.26% during that same timeframe.

adc siic investment strategy

adc siic of belgium invests predominantly in residential real estate properties located around paris and its environs. even with this gain in value, adc siic still stands 11.88% below its 52-week high mark - showing potential for future expansion.

financial instability

though adc siic stock is currently trending upward, it's essential to examine its fundamentals. adc siic's trailing twelve-month earnings per share (eps) stands at eur-0.01, suggesting it's not making profits and its negative return on equity (roe) of -18.77% highlights that shareholders are experiencing difficulty realizing profit from adc siic; such results often suggest ineffective asset management or high debt levels as potential sources for this negative roe figure.

risk evaluation

even though adc siic's recent share price surge may seem encouraging to investors, its negative eps and roe figures hint at financial instability and therefore potential investors should tread with care when considering both risks and rewards associated with investing in adc siic shares.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com